Mablink Bioscience

Mablink Bioscience is a pioneering French biotechnology company developing third-generation antibody-drug conjugates (ADCs) based on proprietary drug linker technology. Since the early 2000s, ADCs have been regarded as highly effective therapeutic biomolecules but have faced major technical obstacles that hinder their full potential in cancer treatment. We have established unique skill continuity and brought together experts in chemistry, pharmacology, and immuno-oncology to develop a readily implementable hydrophilic platform for next-generation ADCs. The patented PSARlink hydrophilic drug linker technology is the core element, circumventing all major limitations in ADC development and enabling the formulation of third-generation ADCs. PSARlink technology paves the way for a new generation of highly hydrophilic, better-tolerated, high-payload ADCs. Our goal is to actively contribute to collaborative efforts aimed at advancing safer and more efficient ADC candidates into clinical trials, ultimately providing new treatment options for cancer patients.